前列腺放疗后腰骶丛神经病两例报告
本文报告两例前列腺放疗后疑似腰骶丛神经病(RILSP)病例,通过临床、影像与剂量学回顾分析发现,局灶高剂量几何分布(尤其是最大点剂量)可能与严重神经毒性相关,提示应关注丛轮廓勾画与最大剂量限制。
要点
- 局灶高剂量重叠腰骶丛可能致严重神经毒性,独立于处方剂量。
- 前列腺放疗中应常规勾画腰骶丛并关注最大点剂量。
- 临床进展与影像不符时需多学科轨迹再评估。
核心结论
- 局灶高剂量几何分布至腰骶丛,尤其最大点剂量,可能促进临床显著神经毒性,超越处方剂量本身。
研究设计与样本
- 两例前列腺放疗后疑似RILSP病例报告,含临床、影像与剂量学回顾分析。
主要发现
- 病例1为75岁男性 salvage 盆腔放疗加局灶推量,治疗后4周出现进行性单侧疼痛无力,进展为双侧神经功能下降并轮椅依赖,回顾勾画示丛Dmax 72.3 Gy且≥70 Gy等剂量线与症状丛段直接重叠。
- 病例2为65岁男性根治性盆腔放疗联合强化雄激素剥夺治疗,治疗后1月出现亚急性双侧近端无力与神经病理性疼痛,肌电图提示丛病但无压迫病变,回顾勾画示Dmax 58.6 Gy且无>65 Gy剂量或局灶推量汇聚。
- 病例2经康复及停用恩扎卢胺后神经功能显著恢复。
关键数值与推荐
- 病例1:腰骶丛Dmax 72.3 Gy,≥70 Gy等剂量线与症状丛段直接重叠。
- 病例2:腰骶丛Dmax 58.6 Gy,无>65 Gy可测剂量。
临床怎么用
- 前列腺放疗中考虑常规勾画腰骶丛并关注最大点剂量以降低严重神经毒性风险。
- 临床进展与预期影像不符时进行基于轨迹的多学科再评估。
- PSMA PET引导靶区扩展与局灶剂量提升时更需注意丛剂量。
局限性
- 仅两例病例报告,不能确立因果关系。
- 回顾性剂量学分析,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiation-induced lumbosacral plexopathy (RILSP) is an uncommon but potentially devastating complication of pelvic radiotherapy. Most published series involve gynecologic or colorectal malignancies, and limited data exist regarding plexus dosimetry and clinical presentation following contemporary prostate radiotherapy. We report two cases of suspected RILSP following prostate radiotherapy with detailed clinical, radiographic, and dosimetric correlation. Case 1 involved a 75-year-old man who underwent salvage pelvic radiotherapy with focal boost for recurrent prostate cancer. Four weeks after treatment completion, he developed progressive unilateral pain and weakness that evolved into bilateral neurologic decline and eventual wheelchair dependence despite lumbar decompression, vitamin B12 repletion, and empiric immunotherapy. Retrospective contouring of the lumbosacral plexus demonstrated focal high-dose exposure with a maximum dose (Dmax) of 72.3 Gy and direct overlap between the ≥70 Gy isodose line and the symptomatic plexus segment. Re-optimization reduced but did not eliminate hotspot overlap because of anatomic constraints. Case 2 involved a 65-year-old man treated with definitive pelvic radiotherapy and intensified androgen deprivation therapy for node-positive prostate cancer. He developed subacute bilateral proximal weakness and neuropathic pain one month after treatment completion. Electromyography raised concern for plexopathy, but no compressive lesion was identified. Retrospective plexus contouring demonstrated substantially lower exposure (Dmax 58.6 Gy) without measurable dose above 65 Gy or focal boost convergence. Following rehabilitation and discontinuation of enzalutamide, the patient experienced substantial neurologic recovery. These contrasting cases suggest that focal high-dose geometry to the lumbosacral plexus, particularly maximum point dose, may contribute to clinically significant neurologic toxicity beyond prescription dose alone. They also highlight the importance of trajectory-based multidisciplinary reassessment when clinical progression diverges from expected imaging findings. As prostate-specific membrane antigen positron emission tomography increasingly guides target expansion and focal dose escalation in prostate radiotherapy, routine plexus contouring and attention to maximum dose may become increasingly important to reduce the risk of severe neural morbidity.
引用
- Kornienko A, Remonde D, Zlotecki R, et al. Radiation-Induced Lumbosacral Plexopathy Following Prostate Radiotherapy. Pract Radiat Oncol. 2026. PMID: 42777859. doi:10.1016/j.prro.2026.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。